(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基)

(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基)

英文名称:Cog 133 trifluoroacetate
CAS号:2828432-37-5
分子式:C99H182F3N37O21
分子量:2283.78
EINECS号:
Mol文件:2828432-37-5.mol
(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基) 结构式

(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基) 性质

形态 固体
颜色 白色至米白色
序列 Ac-Leu-Arg-Val-Arg-Leu-Ala-Ser-His-Leu-Arg-Lys-Leu-Arg-Lys-Arg-Leu-Leu-NH2

(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基) 用途与合成方法

(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基) 是载脂蛋白 E (Apolipoprotein E, APOE) 肽的片段。COG 133 与 ApoE 全息蛋白竞争结合 LDL 受体,具有有效的抗炎和神经保护作用。COG 133 TFA 也是 nAChR 拮抗剂,IC50 为 445 nM。

(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基) 价格(试剂级)

更新日期 产品编号 产品名称 CAS号 包装 价格
2026-09-15 HY-P1050A (S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基) 2828432-37-5 1 mg 1200
2026-09-15 HY-P1050A (S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基) 2828432-37-5 5 mg 2500

(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基)供应商 更多

毕佳索(上海毕得医药科技股份有限公司)
联系电话:400-6005915
产品介绍:
中文名称:(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基)
英文名称:Cog 133 trifluoroacetate
CAS:2828432-37-5
纯度:98%
包装信息:100mg;250mg;1g

"(S)-2-((2S,5S,8S,11S,14S,17S,20S,23S,26S,29S)-8-((1H-咪唑-5-基)甲基)-2,20,26- 三(3-胍基丙基)-11-(羟甲基)-5,17,29-三异丁基-23-异丙基-14-甲基-4,7,10,13,16,19,22,25,28,31-十氧代 -3,6,9,12,15,18,21,24,27,30-十氮杂三甲酰胺)-6-氨基-N-((4S,7S,10S,13S,16S,19S)-13-(4- 氨基丁基)-4-氨基甲酰基-10,16-双(3-胍基丙基)"相关产品信息